RecruitingNCT06452862

Multimodal Magnetic Resonance Imaging in Evaluation of Diabetic Kidney Disease

the Value of Multimodal Magnetic Resonance Imaging in the Diagnosis and Treatment Monitoring of Diabetic Kidney Disease

Sponsor

Shengjing Hospital

Enrollment

150 participants

Start Date

Jun 6, 2024

Study Type

OBSERVATIONAL

Conditions

Diabetic Kidney Disease

Summary

The goal of this study is to investigate the value of noninvasive evaluation of multimodal magnetic resonance imaging in diagnosis and treatment of diabetic kidney disease (DKD). We aim to explore the feasibility of multimodal magnetic resonance imaging in the staging diagnosis of DKD, and establish a non-invasive method for evaluating the progression of DKD disease by combining imaging and biochemical indicators. Multimodal magnetic resonance examinations will be performed on diabetic patients with different stages as well as regular follow-up during treatment, in order to investigate the relationship between imaging findings and pathophysiological changes of the kidneys.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria2

Clinically diagnosed diabetic kidney disease (DKD)
Age 18-80 years

Exclusion Criteria5

Malignant tumor, active infection, or life expectancy <1 year
Pregnancy or lactation
MRE contraindications (metal implants, claustrophobia, severe arrhythmia) or poor image quality
eGFR <15 mL/min/1.73m² or receiving renal replacement therapy
Other primary kidney diseases or systemic diseases affecting renal function

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTMagnetic Resonance Imaging

Both Diabetic Kidney Disease (DKD) patients and Healthy Volunteers will undergo MRI protocols including Blood Oxygen Level Dependence (BOLD), Intravoxel Incoherent Motion (IVIM), Arterial Spin Labeling (ASL), T1\&T2-mapping imaging and Magnetic Resonance Elastography (MRE). For Diabetics, blood tests for creatinine and cystatin C, urine test for albumin-to-creatinine ratio (UACR), along with blood pressure measurements, will be taken within a three-day window surrounding the MRE test. Additionally, Diabetics will undergo a renal biopsy to assess the extent of kidney damage.